Bausch & Lomb's shareholders have voted to approve a merger with Warburg Pincus.
Bausch & Lomb's shareholders have voted to approve a merger with Warburg Pincus.
In accordance with the terms of the merger, each outstanding share of common and Class B stock will be cancelled and converted into the right to receive $65 in cash, without interest, less any applicable withholding taxes.
The merger is expected to close early in the fourth quarter of this year.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.